762 F.3d 1338
Fed. Cir.2014Background
- Tyco owns temazepam patents and Restoril brand; Mutual seeks FDA approval for a generic 7.5 mg temazepam.
- Mutual’s ANDA includes a paragraph IV certification asserting noninfringement; Mutual tests using specific surface area measured at 40°C.
- Tyco sued Mutual under 35 U.S.C. § 271(e)(2)(A); the district court granted noninfringement on the '954 patent and stayed antitrust counterclaims.
- Tyco filed a FDA citizen petition after district court noninfringement ruling; FDA approved Mutual’s ANDA while petition was pending.
- District court later granted summary judgment on Mutual’s antitrust counterclaims; court found no sham litigation and limited Walker Process analysis.
- On appeal, the Third Circuit partly affirmed, partly vacated, and remanded for further fact-finding on several issues, including the effect of outgassing temperature on surface area.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether Tyco’s infringement suit was objectively baseless | Mutual argues Bayer/Elan show infringement claims are baseless. | Tyco contends evidence could support infringement under 271(e)(2)(A). | Remand for further factual inquiry on outgassing effect needed. |
| Noerr-Pennington sham litigation standard applied to patent validity | Mutual asserts Tyco’s validity defense was objectively baseless; PRE applies to litigations and petitions. | Tyco argues PRE-based sham standard not misapplied; validity defenses can be reasonable. | Affirmed denial of sham on validity; remanded for further PRE analysis on petition. |
| Whether Tyco’s FDA citizen petition was a sham under PRE | Mutual contends petition aimed to interfere with Mutual’s market and was baseless. | Tyco maintains petition was a legitimate regulatory comment with no antitrust injury proven. | Vacated as to sham finding; remand for PRE analysis including potential antitrust injury. |
| Walker Process fraud claim against Tyco | Mutual claims Tyco knew of fraud in patent procurement and thus lacks immunity. | Tyco argues no proof of deliberate fraud; redacted documents do not prove knowledge of fraud. | Affirmed district court’s Walker Process ruling; no proven fraud. |
Key Cases Cited
- Professional Real Estate Investors, Inc. v. Columbia Pictures Indus., Inc., 508 U.S. 49 (U.S. 1993) (Noerr-Pennington sham standard; objective and subjective elements)
- Bayer AG v. Elan Pharmaceutical Research Corp., 212 F.3d 1241 (Fed. Cir. 2000) (Infringement inquiry depends on likely post-approval product)
- Elan Pharm. v. Bayer, 212 F.3d 1241 (Fed. Cir. 2000) (Posted in Elan citation context; infringement focus on likely sold product)
- Biovail Corp. v. Biovail Corp., 279 F.3d 1340 (Fed. Cir. 2002) (Evidence of actual infringement can affect infringement question)
- Glaxo, Inc. v. Novopharm, Ltd., 110 F.3d 1562 (Fed. Cir. 1997) (Infringement analysis considering likely post-approval product)
- Abbott Laboratories v. TorPharm, Inc., 300 F.3d 1367 (Fed. Cir. 2002) (Other evidence may contradict ANDA representations; creates disputes of fact)
- Nobelpharma AB v. Implant Innovations, Inc., 141 F.3d 1059 (Fed. Cir. 1998) (Relevance of prior art to validity and enforceability)
- FilmTec Corp. v. Hydranautics, 67 F.3d 931 (Fed. Cir. 1995) (Noerr-Pennington and reasonableness of litigation inquiry)
- Intergraph Corp. v. Intel Corp., 195 F.3d 1346 (Fed. Cir. 1999) (Patent/antitrust interplay; complementary objectives)
- Octane Fitness, LLC v. ICON Health & Fitness, Inc., 134 S. Ct. 1749 (S. Ct. 2014) (Chilling effect of antitrust liability in relation to the right to petition)